A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)

PLoS Medicine

Volumn 5, Issue 4, 2008, Pages 0587-0599

  Ballard, Clive ^a   Lana, Marisa Margallo ^b   Theodoulou, Megan ^c   Douglas, Simon ^d   McShane, Rupert ^e   Jacoby, Robin ^c   Kossakowski, Katja ^a   Yu, Ly Mee ^c   Juszczak, Edmund ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Northgate Hospital   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; SINGLE BLIND PROCEDURE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DEMENTIA; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD;

EID: 43249092442     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050076     Document Type: Article

References (42)